TCGA-50-6594-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- OXIDATIVE_PHOSPHORYLATION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.330
- GLYCOLYSIS+0.320
- MYC_TARGETS_V2+0.280
- ADIPOGENESIS+0.230
- MYC_TARGETS_V1+0.210
- E2F_TARGETS+0.200
- PEROXISOME+0.200
- DNA_REPAIR+0.170
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.410
- HEDGEHOG_SIGNALING-0.330
- CHOLESTEROL_HOMEOSTASIS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.260
- UV_RESPONSE_DN-0.250
- TGF_BETA_SIGNALING-0.240
- IL6_JAK_STAT3_SIGNALING-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- INFLAMMATORY_RESPONSE-0.210
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR27320678 | — | — | 0.757 |
| 2 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.732 |
| 3 | 34c0a7a8-8ce8-4a2a-9bce-939eb2f6f1d9 | — | — | 0.731 |
| 4 | SRR17866853 | — | — | 0.731 |
| 5 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.730 |
| 6 | SRR26320065 | — | — | 0.729 |
| 7 | d31b7542-ab53-4c4f-b070-0c50bb195d1c | — | — | 0.725 |
| 8 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.724 |
| 9 | BS_6VPKXXMR | high-grade glioma | — | 0.721 |
| 10 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |